

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH **DEPRESSION**

1. **Pharmacogenomic testing for psychotropic medication selection: A systematic review of the Assurex GeneSight psychotropic test.** *Ontario health technology assessment series* 2017, **17**(4):1-39.
2. Abraham G, Milev R, Stuart Lawson J: **T3 augmentation of SSRI resistant depression.** *Journal of affective disorders* 2006, **91**(2-3):211-215.
3. Adli M, Wiethoff K, Baghai TC, Fisher R, Seemuller F, Laakmann G, Brieger P, Cordes J, Malevani J, Laux G *et al*: **How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial.** *The international journal of neuropsychopharmacology* 2017, **20**(9):721-730.
4. Al Hadithy A (ed.): **Psychiatrynet**; 2019.
5. Aldrich SL, Poweleit EA, Prows CA, Martin LJ, Strawn JR, Ramsey LB: **Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders.** *Front Pharmacol* 2019, **10**:99.
6. Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindstrom L, Hammarlund-Udenaes M: **Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.** *J Psychiatr Res* 2008, **42**(11):884-893.
7. Alevizos B, Alevizos E, Leonardou A, Zervas I: **Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study.** *Psychiatriki* 2012, **23**(2):143-148.
8. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, Glatt CE, Latoussakis V, Kelly RE, Jr., Kanellopoulos D, Klimstra S, Lim KO, Young RC *et al*: **Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression.** *Journal of affective disorders* 2009, **119**(1-3):132-141.
9. American Psychiatric Association: DSM-5 Task Force: **Practice Guideline for the Treatment of Patients with Major Depressive Disorder.** In: *APA Clinical Guideline.* Third Edition edn: American Psychiatric Association; 2010.
10. Andrade C: **Relative Efficacy and Acceptability of Antidepressant Drugs in Adults With Major Depressive Disorder: Commentary on a Network Meta-Analysis.** *The Journal of clinical psychiatry* 2018, **79**(2).
11. Areberg J, Petersen KB, Chen G, Naik H: **Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals.** *Basic & clinical pharmacology & toxicology* 2014, **115**(6):552-559.
12. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L: **5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients**

- treated with citalopram in a 12-weeks follow up study. *Journal of clinical psychopharmacology* 2003, **23**(6):563-567.
13. Arnow BA, Blasey C, Williams LM, Palmer DM, Rekshan W, Schatzberg AF, Etkin A, Kulkarni J, Luther JF, Rush AJ: **Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.** *The American journal of psychiatry* 2015, **172**(8):743-750.
 14. Aronson R, Offman HJ, Joffe RT, Naylor CD: **Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.** *Archives of general psychiatry* 1996, **53**(9):842-848.
 15. Arteaga-Henriquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, Birkenhager TK, Musil R, Muller N, Drexhage HA: **Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD Patients: A systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME Consortium.** *Front Psychiatry* 2019, **10**:458.
 16. Atasayar G, Eryilmaz IE, Karli N, Egeli U, Zarifoglu M, Cecener G, Taskapilioglu O, Tunca B, Yildirim O, Ak S *et al*: **Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response.** *Journal of the neurological sciences* 2016, **366**:149-154.
 17. Bahr R, Lopez A, Rey JA: **Intranasal Esketamine (Spravato(TM)) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant.** *P T* 2019, **44**(6):340-375.
 18. Bakker PR, van Harten PN, van Os J: **Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.** *Molecular psychiatry* 2008, **13**(5):544-556.
 19. Baldwin DS, Montgomery SA, Nil R, Lader M: **Discontinuation symptoms in depression and anxiety disorders.** *The international journal of neuropsychopharmacology* 2007, **10**(1):73-84.
 20. Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E: **The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.** *Journal of psychopharmacology (Oxford, England)* 2016, **30**(3):242-252.
 21. Barbee JG, Conrad EJ, Jamhour NJ: **The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.** *The Journal of clinical psychiatry* 2004, **65**(7):975-981.
 22. Basu A, Chadda RK, Sood M, Kaur H, Kukreti R: **Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study.** *Indian J Med Res* 2015, **142**(1):40-45.

23. Bauer M, Dopfmer S: **Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.** *Journal of clinical psychopharmacology* 1999, **19**(5):427-434.
24. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Moller HJ, Disorders WTFoUD: **World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.** *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2007, **8**(2):67-104.
25. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M: **Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.** *The Journal of clinical psychiatry* 2009, **70**(4):540-549.
26. Bauer M, Dell'osso L, Kasper S, Pitchot W, Dencker Vansvik E, Kohler J, Jorgensen L, Montgomery SA: **Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.** *Journal of affective disorders* 2013, **151**(1):209-219.
27. Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H: **Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.** *International clinical psychopharmacology* 2014, **29**(1):16-25.
28. Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M: **Role of lithium augmentation in the management of major depressive disorder.** *CNS Drugs* 2014, **28**(4):331-342.
29. Bauer M, Hefting N, Lindsten A, Josiassen MK, Hobart M: **A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.** *Acta Neuropsychiatr* 2019, **31**(1):27-35.
30. Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC: **QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.** *Psychosomatics* 2018, **59**(2):105-122.
31. Bennabi D, Charpeaud T, Yroni A, Genty JB, Destouches S, Lancrenon S, Alaili N, Bellivier F, Bougerol T, Camus V *et al*: **Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental.** *BMC psychiatry* 2019, **19**(1):262.
32. Berigan TR, Harazin JS: **Bupropion-Associated Withdrawal Symptoms: A Case Report.** *Primary care companion to the Journal of clinical psychiatry* 1999, **1**(2):50-51.
33. Berigan TR: **Bupropion-Associated Withdrawal Symptoms Revisited: A Case Report.** *Primary care companion to the Journal of clinical psychiatry* 2002, **4**(2):78.

34. Berlim MT, Turecki G: **What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2007, **17**(11):696-707.
35. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A: **The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.** *The Journal of clinical psychiatry* 2007, **68**(6):843-853.
36. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J *et al*: **Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.** *CNS Spectr* 2009, **14**(4):197-206.
37. Bhat V, Kennedy SH: **Recognition and management of antidepressant discontinuation syndrome.** *J Psychiatry Neurosci* 2017, **42**(4):E7-e8.
38. Bijl MJ, Visser LE, Hofman A, Vulto AG, van Gelder T, Stricker BH, van Schaik RH: **Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.** *British journal of clinical pharmacology* 2008, **65**(4):558-564.
39. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA *et al*: **Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment.** *Nat Genet* 2004, **36**(12):1319-1325.
40. Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hebert C, Debonnel G: **Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2009, **19**(7):457-465.
41. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R: **Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.** *The American journal of psychiatry* 2010, **167**(3):281-288.
42. Bobo WV, Shelton RC: **Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.** *Neuropsychiatric Disease and Treatment* 2009, **5**:369-383.
43. Bobo WV, Shelton RC: **Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.** *Expert opinion on pharmacotherapy* 2009, **10**(13):2145-2159.
44. Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF *et al*: **Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination**

- pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.** *Journal of affective disorders* 2011, **133**(3):467-476.
45. Bodkin JA, Lasser RA, Wines JD, Jr., Gardner DM, Baldessarini RJ: **Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.** *The Journal of clinical psychiatry* 1997, **58**(4):137-145.
 46. Boku S, Inoue T, Honma H, Honma H, Nakagawa S, Koyama T: **Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study.** *Human psychopharmacology* 2011, **26**(3):237-241.
 47. Borobia AM, Novalbos J, Guerra-Lopez P, Lopez-Rodriguez R, Tabares B, Rodriguez V, Abad-Santos F, Carcas AJ: **Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers.** *Pharmacological research* 2009, **59**(6):393-398.
 48. Bose A, Tsai J, Li D: **Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.** *Clin Drug Investig* 2012, **32**(6):373-385.
 49. Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Muller DJ, Richter MA: **Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.** *The pharmacogenomics journal* 2014, **14**(2):176-181.
 50. Breitling LP, Twardella D, Hoffmann MM, Witt SH, Treutlein J, Brenner H: **Prospective association of dopamine-related polymorphisms with smoking cessation in general care.** *Pharmacogenomics* 2010, **11**(4):527-536.
 51. British Columbia Guidelines and Protocols Advisory Committee: **Major Depressive Issues in Adults: Appendix D.** In. Edited by Association BCM. Victoria, BC: Guidelines and Protocols Advisory Committee; 2013.
 52. Brockmoller J, Meineke I, Kirchheiner J: **Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects.** *Clinical pharmacology and therapeutics* 2007, **81**(5):699-707.
 53. Bschor T, Baethge C: **No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy.** *Acta psychiatrica Scandinavica* 2010, **121**(3):174-179.
 54. Candy M, Jones L, Williams R, Tookman A, King M: **Psychostimulants for depression.** *The Cochrane database of systematic reviews* 2008(2):CD006722.
 55. Carpenter LL, Yasmin S, Price LH: **A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine.** *Biological psychiatry* 2002, **51**(2):183-188.
 56. Chang M, Tybring G, Dahl ML, Lindh JD: **Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.** *Clinical pharmacokinetics* 2014, **53**(9):801-811.

57. Cheon EJ, Lee KH, Park YW, Lee JH, Koo BH, Lee SJ, Sung HM: **Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study.** *Journal of clinical psychopharmacology* 2017, **37**(2):193-199.
58. Chokka PR, Hankey JR: **Assessment and management of sexual dysfunction in the context of depression.** *Ther Adv Psychopharmacol* 2018, **8**(1):13-23.
59. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT *et al*: **Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.** *Lancet (London, England)* 2018, **391**(10128):1357-1366.
60. Citrome L: **Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.** *Postgraduate medicine* 2010, **122**(4):39-48.
61. Citrome L: **Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?** *International journal of clinical practice* 2015, **69**(9):978-997.
62. Clayton AH, Baker RA, Sheehan JJ, Cain ZJ, Forbes RA, Marler SV, Marcus R, Berman RM, Thase ME: **Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.** *BMC research notes* 2014, **7**:459.
63. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, Dickens C, Ferrier IN, Geddes J, Gilbody S *et al*: **Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.** *Journal of psychopharmacology (Oxford, England)* 2015, **29**(5):459-525.
64. Cooke RG, Joffe RT, Levitt AJ: **T3 augmentation of antidepressant treatment in T4-replaced thyroid patients.** *The Journal of clinical psychiatry* 1992, **53**(1):16-18.
65. Cooper-Kazaz R, Lerer B: **Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors.** *The international journal of neuropsychopharmacology* 2008, **11**(5):685-699.
66. Corya SA, Andersen SW, Detke HC, Kelly LS, Van Campen LE, Sanger TM, Williamson DJ, Dube S: **Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.** *The Journal of clinical psychiatry* 2003, **64**(11):1349-1356.

67. Crepeau-Gendron G, Brown HK, Shorey C, Madan R, Szabuniewicz C, Koh S, Veinish S, Mah L: **Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.** *Journal of affective disorders* 2019, **250**:341-345.
68. Cristancho MA, Thase ME: **Critical appraisal of selegiline transdermal system for major depressive disorder.** *Expert Opin Drug Deliv* 2016, **13**(5):659-665.
69. Crossley NA, Bauer M: **Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.** *The Journal of clinical psychiatry* 2007, **68**(6):935-940.
70. Czerwensky F, Leucht S, Steimer W: **MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?** *The international journal of neuropsychopharmacology* 2013, **16**(9):2103-2109.
71. Das S, Barnwal P, Winston AB, Mondal S, Saha I: **Brexpiprazole: so far so good.** *Ther Adv Psychopharmacol* 2016, **6**(1):39-54.
72. David SP, Strong DR, Munafo MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, Evins EA, Shields PG, Lerman C, Niaura R: **Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.** *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2007, **9**(12):1251-1257.
73. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR, Shields PG, Lerman C, Strong D, McCaffery J *et al*: **Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.** *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2007, **9**(8):821-833.
74. David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafo MR, Bergen AW, Swan GE, Benowitz NL, Tyndale RF *et al*: **Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.** *Addiction* 2013, **108**(12):2202-2211.
75. de Vos A, van der Weide J, Looovers HM: **Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.** *The pharmacogenomics journal* 2011, **11**(5):359-367.
76. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF: **A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants.** *Journal of clinical psychopharmacology* 2003, **23**(1):27-30.
77. Demirbugen Oz M, Uckun Z, Yuce-Artun N, Baskak B, Ozdemir H, Kizil Ozel T, Devrimci Ozguven H, Suzen HS: **The relationship between the serotonin 2A receptor gene - 1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients.** *Human psychopharmacology* 2018, **33**(5):e2673.
78. Doree JP, Des Rosiers J, Lew V, Gendron A, Elie R, Stip E, Tourjman SV: **Quetiapine augmentation of treatment-resistant depression: a comparison with lithium.** *Current medical research and opinion* 2007, **23**(2):333-341.

79. Dreimuller N, Wagner S, Engel A, Braus DF, Roll SC, Elsner S, Tadic A, Lieb K: **Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.** *BMC psychiatry* 2019, **19**(1):24.
80. **Pharmacogenomics guidelines** [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
81. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, Turgeon J: **Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.** *Pharmacogenetics* 2003, **13**(1):39-47.
82. Edwards SJ, Hamilton V, Nherera L, Trevor N: **Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.** *Health technology assessment (Winchester, England)* 2013, **17**(54):1-190.
83. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H: **Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.** *The international journal of neuropsychopharmacology* 2010, **13**(7):917-932.
84. Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D *et al*: **Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2018, **28**(8):945-954.
85. Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K *et al*: **A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.** *Journal of clinical psychopharmacology* 2011, **31**(5):638-642.
86. Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S: **A Review of Novel Antidepressants: A Guide for Clinicians.** *Cureus* 2019, **11**(3):e4185.
87. Fasipe OJ: **The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents.** *IBRO Rep* 2019, **6**:95-110.
88. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM: **Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.** *The American journal of psychiatry* 1994, **151**(9):1372-1374.
89. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF: **Double-blind study of high-dose fluoxetine versus lithium or**

- desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.** *Journal of clinical psychopharmacology* 2002, **22**(4):379-387.
90. Fava M, Thase ME, DeBattista C: **A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.** *The Journal of clinical psychiatry* 2005, **66**(1):85-93.
91. Fava M: **Prospective studies of adverse events related to antidepressant discontinuation.** *The Journal of clinical psychiatry* 2006, **67 Suppl 4**:14-21.
92. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M: **A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).** *Psychotherapy and psychosomatics* 2012, **81**(2):87-97.
93. Fischer AG, Endrass T, Goebel I, Reuter M, Montag C, Kubisch C, Ullsperger M: **Interactive effects of citalopram and serotonin transporter genotype on neural correlates of response inhibition and attentional orienting.** *Neuroimage* 2015, **116**:59-67.
94. Fornaro M, Martino M, Mattei C, Prestia D, Vinciguerra V, De Berardis D, De Pasquale C, Iasevoli F, Mungo S, Fornaro P: **Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2014, **24**(8):1269-1278.
95. Frankel JS, Schwartz TL: **Brexipiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole.** *Ther Adv Psychopharmacol* 2017, **7**(1):29-41.
96. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J: **Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.** *British journal of clinical pharmacology* 1999, **47**(4):450-453.
97. Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J: **The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.** *European journal of clinical pharmacology* 2000, **56**(2):175-180.
98. Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J: **A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.** *International clinical psychopharmacology* 2008, **23**(5):269-275.
99. Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB: **The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder.** *J Psychiatr Res* 2012, **46**(11):1406-1413.

100. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T *et al*: **Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.** *Annals of internal medicine* 2011, **155**(11):772-785.
101. Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, Sturmer T: **Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.** *Journal of clinical psychopharmacology* 2012, **32**(1):114-119.
102. Gendep Investigators, Mars Investigators, Star D Investigators: **Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.** *The American journal of psychiatry* 2013, **170**(2):207-217.
103. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H, Murata Y, Shimoyama R, Ohkubo T, Shimizu T *et al*: **Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.** *Therapeutic drug monitoring* 2003, **25**(4):463-468.
104. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H, Murata Y, Shimoyama R, Ohkubo T, Shimizu T *et al*: **Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.** *Psychopharmacology* 2003, **167**(4):443-448.
105. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH: **Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.** *The Journal of clinical psychiatry* 2013, **74**(11):1101-1107.
106. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML: **Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.** *European journal of clinical pharmacology* 2004, **60**(5):329-336.
107. Gulrez G, Badyal DK, Deswal RS, Sharma A: **Bupropion as an augmenting agent in patients of depression with partial response.** *Basic & clinical pharmacology & toxicology* 2012, **110**(3):227-230.
108. Harter M, Klesse C, Bermejo I, Schneider F, Berger M: **Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline.** *Deutsches Arzteblatt international* 2010, **107**(40):700-708.
109. Hartter S, Grozinger M, Weigmann H, Roschke J, Hiemke C: **Increased bioavailability of oral melatonin after fluvoxamine coadministration.** *Clinical pharmacology and therapeutics* 2000, **67**(1):1-6.

110. Haslemo T, Eliasson E, Jukic MM, Ingelman-Sundberg M, Molden E: **Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.** *British journal of clinical pharmacology* 2019, **85**(1):194-201.
111. Henssler J, Bschor T, Baethge C: **Combining antidepressants in acute treatment of depression: A meta-analysis of 38 studies including 4511 patients.** *Canadian journal of psychiatry Revue canadienne de psychiatrie* 2016, **61**(1):29-43.
112. Henssler J, Kurschus M, Franklin J, Bschor T, Baethge C: **Trajectories of acute antidepressant efficacy: how long to wait for response? A systematic review and meta-analysis of long-term, placebo-controlled acute treatment trials.** *The Journal of clinical psychiatry* 2018, **79**(3).
113. Henssler J, Heinz A, Brandt L, Bschor T: **Antidepressant withdrawal and rebound phenomena.** *Deutsches Arzteblatt international* 2019, **116**(20):355-361.
114. Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H: **Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.** *European journal of clinical pharmacology* 2008, **64**(5):483-487.
115. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, A LL *et al*: **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors.** *Clinical pharmacology and therapeutics* 2015, **98**(2):127-134.
116. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A *et al*: **Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.** *Clinical pharmacology and therapeutics* 2017, **102**(1):37-44.
117. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G *et al*: **AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.** *Pharmacopsychiatry* 2011, **44**(6):195-235.
118. Hobart M, Skuban A, Zhang P, Augustine C, Brewer C, Hefting N, Sanchez R, McQuade RD: **A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder.** *The Journal of clinical psychiatry* 2018, **79**(4).
119. Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C, Brewer C, Sanchez R, McQuade RD: **Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.** *Current medical research and opinion* 2018, **34**(4):633-642.

120. Hobart M, Zhang P, Skuban A, Brewer C, Hefting N, Sanchez R, McQuade RD: **A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder.** *Journal of clinical psychopharmacology* 2019, **39**(3):203-209.
121. Hodgson K, Tansey K, Dernovsek MZ, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D *et al*: **Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.** *Journal of psychopharmacology (Oxford, England)* 2014, **28**(2):133-141.
122. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Muller-Myhsok B, Holsboer F, Binder EB: **Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.** *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2010, **35**(3):727-740.
123. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G *et al*: **Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.** *Archives of general psychiatry* 2007, **64**(7):783-792.
124. Hubacek JA, Pankova A, Stepankova L, Zvolaska K, Adamkova V, Lanska V, Kralikova E: **SNPs within CHRNA5-A3-B4 and CYP2A6/B6 are associated with smoking dependence but not with tobacco dependence treatment outcomes in the Czech population.** *Gene* 2017, **606**:35-38.
125. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, Mors O, Maier W, Hauser J, Souery D *et al*: **Moderation of antidepressant response by the serotonin transporter gene.** *The British journal of psychiatry : the journal of mental science* 2009, **195**(1):30-38.
126. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, Lehtimaki T, Leinonen E, Kampman O: **5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.** *Neuroreport* 2009, **20**(12):1125-1128.
127. Illi A, Poutanen O, Setala-Soikkeli E, Kampman O, Viikki M, Huhtala H, Mononen N, Haraldsson S, Koivisto PA, Leinonen E *et al*: **Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?** *European archives of psychiatry and clinical neuroscience* 2011, **261**(2):95-102.
128. Irene R, Luis MA, Helena DC, David P, Ramon DJ, Inmaculada G: **Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample.** *International journal of psychiatry in clinical practice* 2009, **13**(2):100-108.
129. Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y: **Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia.** *Journal of clinical pharmacology* 2018, **58**(1):74-80.

130. Ishiguro S, Watanabe T, Ueda M, Saeki Y, Hayashi Y, Akiyama K, Saito A, Kato K, Inoue Y, Shimoda K: **Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder.** *European journal of clinical pharmacology* 2011, **67**(12):1213-1221.
131. Ivkovic J, Lindsten A, George V, Eriksson H, Hobart M: **Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia.** *Journal of clinical psychopharmacology* 2019, **39**(1):13-19.
132. Jaquenoud Sirot E, Harenberg S, Vandell P, Lima CA, Perrenoud P, Kemmerling K, Zullino DF, Hilleret H, Crettol S, Jonzier-Perey M *et al*: **Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression.** *Journal of clinical psychopharmacology* 2012, **32**(5):622-629.
133. Jensen B, Regier L: **Antidepressants: Comparison Chart.** In. RxFiles.ca: RxFiles Academic Detailing; 2019.
134. Jha MK, Minhajuddin A, Gadad BS, Greer T, Grannemann B, Soyombo A, Mayes TL, Rush AJ, Trivedi MH: **Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.** *Psychoneuroendocrinology* 2017, **78**:105-113.
135. Jha MK, Malchow AL, Grannemann BD, Rush AJ, Trivedi MH: **Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.** *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2018, **43**(11):2197-2203.
136. Joffe RT, Singer W: **A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants.** *Psychiatry research* 1990, **32**(3):241-251.
137. Joffe RT, Singer W, Levitt AJ, MacDonald C: **A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.** *Archives of general psychiatry* 1993, **50**(5):387-393.
138. Joffe RT, Sokolov ST, Levitt AJ: **Lithium and triiodothyronine augmentation of antidepressants.** *Canadian journal of psychiatry Revue canadienne de psychiatrie* 2006, **51**(12):791-793.
139. Jukic MM, Haslemo T, Molden E, Ingelman-Sundberg M: **Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.** *The American journal of psychiatry* 2018, **175**(5):463-470.
140. Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T: **Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).** *Journal of affective disorders* 2013, **151**(3):899-905.

141. Kamijima K, Yasuda M, Yamamura K, Fukuta Y: **Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder.** *Current medical research and opinion* 2018, **34**(12):2105-2112.
142. Kasper S, Pail G: **Milnacipran: a unique antidepressant?** *Neuropsychiatric Disease and Treatment* 2010, **6**:23-31.
143. Kato M, Serretti A: **Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.** *Molecular psychiatry* 2010, **15**(5):473-500.
144. Kato T, Furukawa TA, Mantani A, Kurata K, Kubouchi H, Hirota S, Sato H, Sugishita K, Chino B, Itoh K *et al*: **Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUND study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial.** *BMC medicine* 2018, **16**(1):103.
145. Katoh Y, Uchida S, Kawai M, Takei N, Mori N, Kawakami J, Kagawa Y, Yamada S, Namiki N, Hashimoto H: **Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.** *Biological & pharmaceutical bulletin* 2010, **33**(2):285-288.
146. Kawaguchi DM, Glatt SJ: **GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis.** *Pharmacogenomics* 2014, **15**(11):1451-1459.
147. Kawanishi C, Lundgren S, Agren H, Bertilsson L: **Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.** *European journal of clinical pharmacology* 2004, **59**(11):803-807.
148. Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, Henigsberg N, Kozel D, Mors O, Maier W *et al*: **Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project.** *The pharmacogenomics journal* 2011, **11**(2):138-145.
149. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB: **A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.** *J Psychiatr Res* 2009, **43**(3):205-214.
150. Keks NA, Burrows GD, Copolov DL, Newton R, Paoletti N, Schweitzer I, Tiller J: **Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression?** *The Medical journal of Australia* 2007, **186**(3):142-144.
151. Keks N, Hope J, Keogh S: **Switching and stopping antidepressants.** *Australian prescriber* 2016, **39**(3):76-83.
152. Keller MB: **Issues in treatment-resistant depression.** *The Journal of clinical psychiatry* 2005, **66 Suppl 8**:5-12.

153. Kelly TF, Lieberman DZ: **Long term augmentation with T3 in refractory major depression.** *Journal of affective disorders* 2009, **115**(1-2):230-233.
154. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM *et al*: **Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments.** *Canadian journal of psychiatry Revue canadienne de psychiatrie* 2016, **61**(9):540-560.
155. Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J, Hollingworth W, Chew-Graham C, Anderson I, Campbell J *et al*: **Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.** *Health technology assessment (Winchester, England)* 2018, **22**(63):1-136.
156. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: **Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.** *Pharmacogenetics* 2002, **12**(7):571-580.
157. Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmoller J: **Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.** *Journal of clinical psychopharmacology* 2004, **24**(6):647-652.
158. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Naitoh H *et al*: **HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.** *Neuromolecular medicine* 2010, **12**(3):237-242.
159. Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C: **Vortioxetine for depression in adults.** *The Cochrane database of systematic reviews* 2017, **7**:Cd011520.
160. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S: **Second-generation antipsychotics for major depressive disorder and dysthymia.** *The Cochrane database of systematic reviews* 2010(12):Cd008121.
161. Kraus C, Kadriu B, Lanzenberger R, Zarate CA, Jr., Kasper S: **Prognosis and improved outcomes in major depression: a review.** *Translational psychiatry* 2019, **9**(1):127.
162. Kumar Y, Kung S, Shinozaki G: **CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.** *Journal of psychopharmacology (Oxford, England)* 2014, **28**(12):1143-1148.
163. Kunugi H, Hori H, Ogawa S: **Biochemical markers subtyping major depressive disorder.** *Psychiatry and clinical neurosciences* 2015, **69**(10):597-608.
164. Lam RW, Hossie H, Solomons K, Yatham LN: **Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression.** *The Journal of clinical psychiatry* 2004, **65**(3):337-340.
165. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV, Canadian Network for M *et al*: **Canadian Network for Mood**

- and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.** *Journal of affective disorders* 2009, **117 Suppl 1**:S26-43.
166. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF: **CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.** *Biological psychiatry* 2007, **62(6)**:635-641.
167. Lee EJ, Oh MS, Kim JS, Chang DI, Park JH, Cha JK, Heo JH, Sohn SI, Kim DE, Kim HY *et al*: **Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use.** *Journal of neurology, neurosurgery, and psychiatry* 2018, **89(3)**:271-276.
168. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ *et al*: **The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.** *Biological psychiatry* 2008, **63(12)**:1103-1110.
169. Lepola U, Hefting N, Zhang D, Hobart M: **Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.** *International journal of geriatric psychiatry* 2018, **33(10)**:1403-1410.
170. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L: **Pharmacogenetic investigation of smoking cessation treatment.** *Pharmacogenetics* 2002, **12(8)**:627-634.
171. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH, Jr., Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH: **Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.** *Health psychology : official journal of the Division of Health Psychology, American Psychological Association* 2003, **22(5)**:541-548.
172. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J: **Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.** *Pharmacogenetics* 1999, **9(4)**:435-443.
173. Leuchter AF, Lesser IM, Trivedi MH, Rush AJ, Morris DW, Warden D, Fava M, Wisniewski SR, Luther JF, Perales M *et al*: **An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.** *Journal of psychiatric practice* 2008, **14(5)**:271-280.
174. Lewis G, Duffy L, Ades A, Amos R, Araya R, Brabyn S, Button KS, Churchill R, Derrick C, Dowrick C *et al*: **The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.** *The lancet Psychiatry* 2019, **6(11)**:903-914.
175. Lin XQ, Wang P, Cai WK, Xu GL, Yang M, Zhou MD, Sun M, He F, He GH: **The associations between CYP2D6 metabolizer status and pharmacokinetics and**

- clinical outcomes of venlafaxine: a systematic review and meta-analysis.** *Pharmacopsychiatry* 2019, **52**(5):222-231.
176. Lind AB, Reis M, Bengtsson F, Jonzier-Perey M, Powell Golay K, Ahlner J, Baumann P, Dahl ML: **Steady-state concentrations of mirtazapine, N-desmethyilmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.** *Clinical pharmacokinetics* 2009, **48**(1):63-70.
177. Linde K, Kriston L, Rucker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A: **Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis.** *Ann Fam Med* 2015, **13**(1):69-79.
178. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT: **Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.** *The Journal of clinical psychiatry* 2010, **71**(11):1482-1487.
179. Long JD: **Vortioxetine for Depression in Adults.** *Issues Ment Health Nurs* 2019, **40**(9):819-820.
180. Lotufo-Neto F, Trivedi M, Thase ME: **Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.** *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 1999, **20**(3):226-247.
181. Luan S, Wan H, Zhang L, Zhao H: **Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials.** *Neuropsychiatric Disease and Treatment* 2018, **14**:467-477.
182. Ma X, Maimaitirexiati T, Zhang R, Gui X, Zhang W, Xu G, Hu G: **HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.** *International journal of psychiatry in clinical practice* 2014, **18**(4):229-242.
183. MacQueen G, Santaguida P, Keshavarz H, Jaworska N, Levine M, Beyene J, Raina P: **Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults.** *Canadian journal of psychiatry Revue canadienne de psychiatrie* 2017, **62**(1):11-23.
184. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM: **Risperidone for treatment-refractory major depressive disorder: a randomized trial.** *Annals of internal medicine* 2007, **147**(9):593-602.
185. Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood M, Lyndon B, Mulder R, Murray G *et al*: **Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.** *The Australian and New Zealand journal of psychiatry* 2015, **49**(12):1087-1206.

186. Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS *et al*: **Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.** *Archives of general psychiatry* 2012, **69**(9):904-912.
187. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM: **The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.** *Journal of clinical psychopharmacology* 2008, **28**(2):156-165.
188. Maron E, Tammiste A, Kallassalu K, Eller T, Vasar V, Nutt DJ, Metspalu A: **Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2009, **19**(6):451-456.
189. Mathews M, Gommoll C, Chen D, Nunez R, Khan A: **Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.** *International clinical psychopharmacology* 2015, **30**(2):67-74.
190. McAlpine DE, O'Kane DJ, Black JL, Mrazek DA: **Cytochrome P450 2D6 genotype variation and venlafaxine dosage.** *Mayo Clinic proceedings* 2007, **82**(9):1065-1068.
191. **SwitchRx** [<https://www.switchrx.com/antidepressants.php/switch>]
192. McIntyre RS, Gommoll C, Chen C, Ruth A: **The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.** *CNS Spectr* 2016, **21**(5):385-392.
193. McIntyre RS: **The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone.** *Neuropsychiatric Disease and Treatment* 2017, **13**:2913-2919.
194. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M *et al*: **Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.** *American journal of human genetics* 2006, **78**(5):804-814.
195. Min W, Li T, Ma X, Li Z, Yu T, Gao D, Zhang B, Yun Y, Sun X: **Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response.** *Psychopharmacology* 2009, **205**(3):409-417.
196. Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M: **Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.** *The Journal of clinical psychiatry* 2012, **73**(3):353-357.

197. Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I *et al*: **Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: The VAST-D randomized clinical trial.** *Jama* 2017, **318**(2):132-145.
198. Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, Schaid DJ, Drews MS, Courson VL, Snyder KA *et al*: **SLC6A4 variation and citalopram response.** *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2009, **150B**(3):341-351.
199. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, Snyder KA, Stevens SR, Rush AJ, Weinshilboum RM: **CYP2C19 variation and citalopram response.** *Pharmacogenetics and genomics* 2011, **21**(1):1-9.
200. Muench J, Hamer AM: **Adverse effects of antipsychotic medications.** *American family physician* 2010, **81**(5):617-622.
201. Mulder H, Franke B, van der-BEEK van der AA, Arends J, Wilmink FW, Scheffer H, Egberts AC: **The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.** *Journal of clinical psychopharmacology* 2007, **27**(4):338-343.
202. Mulder H, Cohen D, Scheffer H, Gispens-de Wied C, Arends J, Wilmink FW, Franke B, Egberts AC: **HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.** *Journal of clinical psychopharmacology* 2009, **29**(1):16-20.
203. Muller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N *et al*: **Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.** *The pharmacogenomics journal* 2012, **12**(2):156-164.
204. Muller DJ, Brandl EJ, Hwang R, Tiwari AK, Sturgess JE, Zai CC, Lieberman JA, Kennedy JL, Richter MA: **The AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.** *Genetic testing and molecular biomarkers* 2012, **16**(8):897-903.
205. Murphy GM, Jr., Kremer C, Rodrigues HE, Schatzberg AF: **Pharmacogenetics of antidepressant medication intolerance.** *The American journal of psychiatry* 2003, **160**(10):1830-1835.
206. Muzina DJ, Chambers JS, Camacho TA, Eudicone JM, Forbes RA, Berman RM, Baker RA: **Adjunctive aripiprazole for depression: predictive value of early assessment.** *The American journal of managed care* 2011, **17**(12):793-801.

207. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA: **Milnacipran versus other antidepressive agents for depression.** *The Cochrane database of systematic reviews* 2009(3):CD006529.
208. Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T, Takeuchi H, Abe T, Kashima H, Mimura M: **Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial.** *Progress in neuro-psychopharmacology & biological psychiatry* 2011, **35**(8):1983-1989.
209. Nasr S, Wendt B, Popli A, Crayton J: **Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion.** *Journal of affective disorders* 2014, **162**:50-54.
210. National Institute for Health and Care Evidence: **Depression in adults: recognition and management [Clinical Guideline CG90].** 2009.
211. National Institute for Health and Care Evidence: **Depression in Adults with a Chronic Physical Health Problem: Treatment and Management [NICE Guideline CG90].** In.; 2010.
212. National Institute for Health and Care Excellence: **Depression Evidence Update: A summary of selected new evidence relevant to NICE clinical guideline 90 'The treatment and management of depression in adults'.** In.; 2012.
213. Nelson JC, Thase ME, Trivedi MH, Fava M, Han J, Van Tran Q, Pikalov A, Qi Y, Carlson BX, Marcus RN *et al*: **Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163).** *Primary care companion to the Journal of clinical psychiatry* 2009, **11**(6):344-352.
214. Nelson JC, Papakostas GI: **Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.** *The American journal of psychiatry* 2009, **166**(9):980-991.
215. Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, Marcus RN, Baker RA, Sheehan JJ: **Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.** *CNS Spectr* 2014, **19**(6):528-534.
216. Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C: **A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression.** *Journal of affective disorders* 2014, **168**:269-275.
217. Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I: **Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.** *Human psychopharmacology* 2013, **28**(5):516-522.

218. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M: **Early nonresponse to fluoxetine as a predictor of poor 8-week outcome.** *The American journal of psychiatry* 1995, **152**(10):1500-1503.
219. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M: **Timing of onset of antidepressant response with fluoxetine treatment.** *The American journal of psychiatry* 2000, **157**(9):1423-1428.
220. Nierenberg AA, Papakostas GI, Petersen T, Montoya HD, Worthington JJ, Tedlow J, Alpert JE, Fava M: **Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants.** *Journal of clinical psychopharmacology* 2003, **23**(1):92-95.
221. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G *et al*: **A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.** *The American journal of psychiatry* 2006, **163**(9):1519-1530; quiz 1665.
222. Niitsu T, Fabbri C, Bentini F, Serretti A: **Pharmacogenetics in major depression: a comprehensive meta-analysis.** *Progress in neuro-psychopharmacology & biological psychiatry* 2013, **45**:183-194.
223. Nishimura M, Ueda M, Saruwatari J, Nakashima H, Ogusu N, Aoki A, Tsuchimine S, Matsuda K, Iwashita K, Ono T *et al*: **Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.** *Pharmacogenetics and genomics* 2016, **26**(9):403-413.
224. Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, Linotte S, Mendlewicz J, Montgomery S, Snyder L *et al*: **5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.** *International clinical psychopharmacology* 2010, **25**(4):228-231.
225. Ohara K, Nagai M, Tani K, Nakamura Y, Ino A, Ohara K: **Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia.** *Psychiatry research* 1998, **81**(2):117-123.
226. Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H: **CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects.** *European journal of clinical pharmacology* 2003, **58**(10):659-661.
227. Outhred T, Das P, Dobson-Stone C, Felmingham KL, Bryant RA, Nathan PJ, Malhi GS, Kemp AH: **Impact of 5-HTTLPR on SSRI serotonin transporter blockade during emotion regulation: A preliminary fMRI study.** *Journal of affective disorders* 2016, **196**:11-19.
228. Owenby RK, Brown LT, Brown JN: **Use of risperidone as augmentation treatment for major depressive disorder.** *The Annals of pharmacotherapy* 2011, **45**(1):95-100.
229. Ozaki N, Otsubo T, Kato M, Higuchi T, Ono H, Kamijima K: **Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup**

- analysis and Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.** *Psychiatry and clinical neurosciences* 2015, **69**(1):34-42.
230. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ: **Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.** *The American journal of psychiatry* 2007, **164**(8):1181-1188.
231. Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N: **Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis.** *Current medical research and opinion* 2017, **33**(4):701-711.
232. Papakostas GI, Fava M: **A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.** *Canadian journal of psychiatry Revue canadienne de psychiatrie* 2006, **51**(12):783-790.
233. Papakostas GI, Worthington JJ, 3rd, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M: **The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.** *Depression and anxiety* 2006, **23**(3):178-181.
234. Papakostas GI, Fava M: **A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2007, **17**(1):32-36.
235. Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC: **Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.** *The American journal of psychiatry* 2015, **172**(12):1251-1258.
236. Park LT, Zarate CA, Jr.: **Depression in the Primary Care Setting.** *The New England journal of medicine* 2019, **380**(6):559-568.
237. Parker G, Brotchie H, Parker K: **Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone?** *The American journal of psychiatry* 2005, **162**(4):796-798.
238. Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK: **Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant.** *Ther Adv Psychopharmacol* 2016, **6**(2):99-144.
239. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J *et al*: **A randomized, double-blind comparison of duloxetine**

- and venlafaxine in the treatment of patients with major depressive disorder.** *J Psychiatr Res* 2008, **42**(1):22-34.
240. Perahia DG, Quail D, Desai D, Corruble E, Fava M: **Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques.** *The Journal of clinical psychiatry* 2008, **69**(1):95-105.
241. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, Kraft JB, McGrath PJ, Hamilton SP: **Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response.** *Pharmacogenetics and genomics* 2009, **19**(1):1-10.
242. Petry N, Lupu R, Gohar A, Larson EA, Peterson C, Williams V, Zhao J, Wilke RA, Hines LJ: **CYP2C19 genotype, physician prescribing pattern, and risk for long QT on serotonin selective reuptake inhibitors.** *Pharmacogenomics* 2019, **20**(5):343-351.
243. Poland RE, Lesser IM, Wan YJ, Gertsik L, Yao J, Raffel LJ, Lin KM, Myers HF: **Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression.** *Life Sci* 2013, **92**(20-21):967-970.
244. Porcelli S, Fabbri C, Serretti A: **Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2012, **22**(4):239-258.
245. Posternak M, Novak S, Stern R, Hennessey J, Joffe R, Prange A, Jr., Zimmerman M: **A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response.** *The international journal of neuropsychopharmacology* 2008, **11**(1):15-25.
246. Poweleit EA, Aldrich SL, Martin LJ, Hahn D, Strawn JR, Ramsey LB: **Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders.** *Journal of child and adolescent psychopharmacology* 2019, **29**(5):348-361.
247. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: **Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.** *Journal of clinical psychopharmacology* 2009, **29**(1):39-43.
248. Pu M, Zhang Z, Xu Z, Shi Y, Geng L, Yuan Y, Zhang X, Reynolds GP: **Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response.** *Pharmacogenomics* 2013, **14**(3):277-288.
249. Ramanuj P, Ferenchick EK, Pincus HA: **Depression in primary care: part 2- management.** *BMJ* 2019, **365**:l835.
250. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P *et al*: **Effects of risperidone augmentation in**

- patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.** *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* 2006, **31**(11):2505-2513.
251. Risselada AJ, Mulder H, Heerdink ER, Gonera RK, Egberts TCG: **Association between the HTR2C rs1414334 and ADRA2A 1291 C/G polymorphisms and lipid levels in obese patients.** In: *Genetic determinants for metabolic abnormalities*. edn.; 2012: 107.
252. Rocha FL, Fuzikawa C, Riera R, Hara C: **Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis.** *Journal of clinical psychopharmacology* 2012, **32**(2):278-281.
253. Romera I, Perez V, Menchon JM, Schacht A, Papen R, Neuhauser D, Abbar M, Picard H, Gilaberte I: **Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.** *Journal of affective disorders* 2012, **143**(1-3):47-55.
254. Rosenthal LJ, Goldner WS, O'Reardon JP: **T3 augmentation in major depressive disorder: safety considerations.** *The American journal of psychiatry* 2011, **168**(10):1035-1040.
255. Rotberg B, Kronenberg S, Carmel M, Frisch A, Brent D, Zalsman G, Apter A, Weizman A: **Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders.** *Journal of child and adolescent psychopharmacology* 2013, **23**(2):117-122.
256. Rudberg I, Hermann M, Refsum H, Molden E: **Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients.** *European journal of clinical pharmacology* 2008, **64**(12):1181-1188.
257. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM *et al*: **Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.** *Control Clin Trials* 2004, **25**(1):119-142.
258. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM *et al*: **Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.** *The American journal of psychiatry* 2011, **168**(7):689-701.
259. Ryu S, Park S, Lee JH, Kim YR, Na HS, Lim HS, Choi HY, Hwang IY, Lee JG, Park ZW *et al*: **A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans.** *Clinical and translational science* 2017, **10**(2):93-101.
260. Saiz-Rodriguez M, Belmonte C, Derqui-Fernandez N, Cabaleiro T, Roman M, Ochoa D, Talegon M, Ovejero-Benito MC, Abad-Santos F: **Pharmacogenetics of trazodone in**

- healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety.** *Pharmacogenomics* 2017, **18**(16):1491-1502.
261. Saiz-Rodriguez M, Belmonte C, Roman M, Ochoa D, Jiang-Zheng C, Koller D, Mejia G, Zubiaur P, Wojnicz A, Abad-Santos F: **Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants.** *Basic & clinical pharmacology & toxicology* 2018, **123**(4):474-485.
262. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC: **Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research.** *The Journal of clinical psychiatry* 2006, **67** Suppl 4:27-30.
263. Schindler F, Anghelescu IG: **Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study.** *International clinical psychopharmacology* 2007, **22**(3):179-182.
264. Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S: **A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.** *Acta psychiatrica Scandinavica* 2011, **123**(4):247-265.
265. Serretti A, Kato M, De Ronchi D, Kinoshita T: **Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients.** *Molecular psychiatry* 2007, **12**(3):247-257.
266. Serretti A: **The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants.** *Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology* 2018, **16**(1):1-6.
267. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: **CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.** *Journal of clinical pharmacy and therapeutics* 2006, **31**(5):493-502.
268. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA *et al*: **A novel augmentation strategy for treating resistant major depression.** *The American journal of psychiatry* 2001, **158**(1):131-134.
269. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD: **Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.** *The Journal of clinical psychiatry* 2005, **66**(10):1289-1297.
270. Shiroma PR, Drews MS, Geske JR, Mrazek DA: **SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.** *The American*

- journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry* 2014, **22**(11):1140-1148.
271. Sokolov ST, Levitt AJ, Joffe RT: **Thyroid hormone levels before unsuccessful antidepressant therapy are associated with later response to T3 augmentation.** *Psychiatry research* 1997, **69**(2-3):203-206.
272. Solmi M, Veronese N, Zaninotto L, van der Loos ML, Gao K, Schaffer A, Reis C, Normann C, Anghelescu IG, Correll CU: **Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.** *CNS Spectr* 2016, **21**(5):403-418.
273. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV *et al*: **Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.** *Ther Clin Risk Manag* 2017, **13**:757-777.
274. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC: **Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes.** *PLoS medicine* 2013, **10**(3):e1001403.
275. Spier SA: **Use of bupropion with SRIs and venlafaxine.** *Depression and anxiety* 1998, **7**(2):73-75.
276. Spigset O, Axelsson S, Norstrom A, Hagg S, Dahlqvist R: **The major fluvoxamine metabolite in urine is formed by CYP2D6.** *European journal of clinical pharmacology* 2001, **57**(9):653-658.
277. Stahl SM: **Mechanism of action of brexpiprazole: comparison with aripiprazole.** *CNS Spectr* 2016, **21**(1):1-6.
278. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S: **Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.** *Clinical chemistry* 2005, **51**(2):376-385.
279. Stewart JW, McGrath PJ, Blondeau C, Deliyannides DA, Hellerstein D, Norris S, Amat J, Pilowsky DJ, Tessier P, Laberge L *et al*: **Combination antidepressant therapy for major depressive disorder: speed and probability of remission.** *J Psychiatr Res* 2014, **52**:7-14.
280. Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL, Taylor R, Mantingh T, de Angel V, Patrick F *et al*: **Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis.** *The British journal of psychiatry : the journal of mental science* 2019, **214**(1):42-51.
281. Strohmaier J, Wust S, Uher R, Henigsberg N, Mors O, Hauser J, Souery D, Zobel A, Dernovsek MZ, Streit F *et al*: **Sexual dysfunction during treatment with serotonergic**

- and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR.** *The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry* 2011, **12**(7):528-538.
282. Sugawara H, Sakamoto K, Harada T, Ishigooka J: **Predictors of efficacy in lithium augmentation for treatment-resistant depression.** *Journal of affective disorders* 2010, **125**(1-3):165-168.
283. Suzuki Y, Sawamura K, Someya T: **Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.** *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* 2006, **31**(4):825-831.
284. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Inoue Y, Ozdemir V, Someya T: **CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.** *Journal of psychopharmacology (Oxford, England)* 2011, **25**(7):908-914.
285. Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, Curry SJ, McAfee T: **Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.** *The pharmacogenomics journal* 2005, **5**(1):21-29.
286. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines.** *Clinical pharmacology and therapeutics* 2011, **89**(5):662-673.
287. Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O: **Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.** *The Journal of clinical psychiatry* 2003, **64**(4):413-420.
288. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME: **Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.** *The Journal of clinical psychiatry* 2009, **70**(3):344-353.
289. Tatham EL, Hall GB, Clark D, Foster J, Ramasubbu R: **The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinat fasciculus connectivity and antidepressants treatment response in major depression.** *European archives of psychiatry and clinical neuroscience* 2017, **267**(2):135-147.
290. Taylor D, Stewart S, Connolly A: **Antidepressant withdrawal symptoms-telephone calls to a national medication helpline.** *Journal of affective disorders* 2006, **95**(1-3):129-133.

291. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K: **Strategies for managing sexual dysfunction induced by antidepressant medication.** *The Cochrane database of systematic reviews* 2013(5):CD003382.
292. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dube S: **A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.** *The Journal of clinical psychiatry* 2007, **68**(2):224-236.
293. Thase ME: **No evidence for switching antidepressants in treatment-resistant depressed patients.** *Evid Based Med* 2010, **15**(4):120-121.
294. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R *et al*: **Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.** *The Journal of clinical psychiatry* 2015, **76**(9):1224-1231.
295. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H: **Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.** *The Journal of clinical psychiatry* 2015, **76**(9):1232-1240.
296. Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E: **Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2017, **27**(8):773-781.
297. The Management of Major Depressive Disorder Working Group: **VA/DoD Clinical practice guideline for the management of major depressive disorder.** In., vol. v3: Department of Veterans Affairs, Department of Defense; 2016.
298. Tomaz PR, Santos JR, Issa JS, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PC: **CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.** *European journal of clinical pharmacology* 2015, **71**(9):1067-1073.
299. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM *et al*: **Medication augmentation after the failure of SSRIs for depression.** *The New England journal of medicine* 2006, **354**(12):1243-1252.
300. Turner P, Kantaria R, Young AH: **A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective.** *Journal of psychopharmacology (Oxford, England)* 2014, **28**(2):85-98.
301. Valerio MP, Martino DJ: **Differential response to lithium between melancholic and non-melancholic unipolar depression.** *Psychiatry research* 2018, **269**:183-184.

302. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE: **Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.** *Therapeutic drug monitoring* 2005, **27**(4):478-483.
303. Van Nieuwerburgh FC, Denys DA, Westenberg HG, Deforce DL: **Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.** *International journal of psychiatry in clinical practice* 2009, **13**(1):345-348.
304. Veeffkind AH, Haffmans PM, Hoencamp E: **Venlafaxine serum levels and CYP2D6 genotype.** *Therapeutic drug monitoring* 2000, **22**(2):202-208.
305. Veldic M, Ahmed AT, Blacker CJ, Geske JR, Biernacka JM, Borreggine KL, Moore KM, Prieto ML, Vande Voort JL, Croarkin PE *et al*: **Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications.** *Front Pharmacol* 2019, **10**:83.
306. Viikki M, Huuhka K, Leinonen E, Illi A, Setälä-Soikkeli E, Huuhka M, Mononen N, Lehtimäki T, Kampman O: **Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD.** *Neuroscience letters* 2011, **501**(1):20-24.
307. Waade RB, Hermann M, Moe HL, Molden E: **Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.** *European journal of clinical pharmacology* 2014, **70**(8):933-940.
308. Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G: **Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.** *Journal of affective disorders* 2018, **228**:1-12.
309. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, Zhou HH: **Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.** *Clinical pharmacology and therapeutics* 2001, **70**(1):42-47.
310. Wang HR, Woo YS, Ahn HS, Ahn IM, Kim HJ, Bahk WM: **Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance? A meta-analysis of randomized controlled trials.** *The international journal of neuropsychopharmacology* 2015, **18**(8).
311. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU: **Vilazodone for the treatment of depression: an update.** *Chonnam Med J* 2016, **52**(2):91-100.
312. Warner CH, Bobo W, Warner C, Reid S, Rachal J: **Antidepressant discontinuation syndrome.** *American family physician* 2006, **74**(3):449-456.
313. Watanabe J, Suzuki Y, Fukui N, Sugai T, Ono S, Inoue Y, Someya T: **Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.** *Therapeutic drug monitoring* 2008, **30**(6):705-708.

314. Working group of the clinical practice guideline on the management of depression in adults: **Clinical practice guideline on the management of depression in adults**. In: *Clinical practice guidelines in the Spanish NHS*. 2014.
315. Yevtushenko OO, Oros MM, Reynolds GP: **Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism**. *Journal of affective disorders* 2010, **123**(1-3):308-311.
316. Yoon S, Jeon SW, Ko YH, Patkar AA, Masand PS, Pae CU, Han C: **Adjunctive brexpiprazole as a novel effective strategy for treating major depressive disorder: A systematic review and meta-analysis**. *Journal of clinical psychopharmacology* 2017, **37**(1):46-53.
317. Yoshimura R, Hori H, Umene-Nakano W, Ikenouchi-Sugita A, Katsuki A, Atake K, Nakamura J: **Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder**. *Ther Adv Psychopharmacol* 2014, **4**(3):123-129.
318. Young AH, Evitt L, Brignone M, Diamand F, Atsou K, Campbell R, Cure S, Danchenko N: **Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom**. *Journal of affective disorders* 2017, **218**:291-298.
319. Zafra-Tanaka JH, Goicochea-Lugo S, Villarreal-Zegarra D, Taype-Rondan A: **Characteristics and quality of clinical practice guidelines for depression in adults: a scoping review**. *BMC psychiatry* 2019, **19**(1):76.
320. Zai CC, De Luca V, Hwang RW, Voineskos A, Muller DJ, Remington G, Kennedy JL: **Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients**. *Molecular psychiatry* 2007, **12**(9):794-795.
321. Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA: **Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder**. *Pharmacogenomics and personalized medicine* 2018, **11**:113-119.
322. Zhang JP, Lencz T, Malhotra AK: **D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis**. *The American journal of psychiatry* 2010, **167**(7):763-772.
323. Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, John M, Robinson DG, Fleischhacker WW, Kahn RS, Ophoff RA *et al*: **Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis**. *Schizophrenia bulletin* 2016, **42**(6):1418-1437.
324. Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, Zhao J, Liu Y, Fang Y, Zhang Y *et al*: **Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis**. *The international journal of neuropsychopharmacology* 2015, **18**(11):pyv060.

325. Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y *et al*: **Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.** *The Journal of clinical psychiatry* 2015, **76**(4):e487-498.
326. Zou YF, Wang F, Feng XL, Li WF, Tao JH, Pan FM, Huang F, Su H: **Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders.** *Neuroscience letters* 2010, **484**(1):56-61.